CLINICAL TRIALS PROFILE FOR TENECTEPLASE

All Clinical Trials for tenecteplase

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00064428 ↗	OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction	Completed	Sanofi	Phase 3	2003-08-01	This is a randomized, double blindcontrolled, parallel group, multi-center, multinational study of fondaparinux vs. control in patients with STEMI (ST segment myocardial infarction) randomized within 24 hours of the onset of symptoms.
NCT00064428 ↗	OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction	Completed	GlaxoSmithKline	Phase 3	2003-08-01	This is a randomized, double blindcontrolled, parallel group, multi-center, multinational study of fondaparinux vs. control in patients with STEMI (ST segment myocardial infarction) randomized within 24 hours of the onset of symptoms.
NCT00121446 ↗	Which Therapy for Acute Heart Attacks? (The WEST Study)	Completed	Eli Lilly and Company	Phase 2/Phase 3	2003-07-01	In the setting of acute myocardial infarction (heart attacks), the principle objective of the WEST Study is to compare the impact on clinical outcomes of 3 different treatment strategies. The first is using medical (drug) therapy alone with standard care. The second strategy is identical medical (drug) therapy as the first group combined with early heart catheterization (within 24 hours) for angiography and if required, intervention. The third treatment strategy is direct admission (within 3 hrs) to the heart catheterization lab for angioplasty. WEST patients will be enrolled at first medical contact (using emergency medical services, e.g. ambulance) if possible or through Emergency Departments in participating health care facilities.
NCT00121446 ↗	Which Therapy for Acute Heart Attacks? (The WEST Study)	Completed	Hoffmann-La Roche	Phase 2/Phase 3	2003-07-01	In the setting of acute myocardial infarction (heart attacks), the principle objective of the WEST Study is to compare the impact on clinical outcomes of 3 different treatment strategies. The first is using medical (drug) therapy alone with standard care. The second strategy is identical medical (drug) therapy as the first group combined with early heart catheterization (within 24 hours) for angiography and if required, intervention. The third treatment strategy is direct admission (within 3 hrs) to the heart catheterization lab for angioplasty. WEST patients will be enrolled at first medical contact (using emergency medical services, e.g. ambulance) if possible or through Emergency Departments in participating health care facilities.
NCT00121446 ↗	Which Therapy for Acute Heart Attacks? (The WEST Study)	Completed	Sanofi	Phase 2/Phase 3	2003-07-01	In the setting of acute myocardial infarction (heart attacks), the principle objective of the WEST Study is to compare the impact on clinical outcomes of 3 different treatment strategies. The first is using medical (drug) therapy alone with standard care. The second strategy is identical medical (drug) therapy as the first group combined with early heart catheterization (within 24 hours) for angiography and if required, intervention. The third treatment strategy is direct admission (within 3 hrs) to the heart catheterization lab for angioplasty. WEST patients will be enrolled at first medical contact (using emergency medical services, e.g. ambulance) if possible or through Emergency Departments in participating health care facilities.

Clinical Trial Conditions for tenecteplase

Condition Name

Condition Name for tenecteplase
Intervention	Trials
Acute Ischemic Stroke	24
Ischemic Stroke	19
Myocardial Infarction	12
Stroke	10

Condition MeSH

Condition MeSH for tenecteplase
Intervention	Trials
Ischemic Stroke	66
Stroke	50
Ischemia	26
Infarction	16

Clinical Trial Locations for tenecteplase

Trials by Country

Trials by Country for tenecteplase
Location	Trials
China	126
United States	66
Canada	38
Australia	37
Norway	10

Trials by US State

Trials by US State for tenecteplase
Location	Trials
California	5
North Carolina	4
Massachusetts	4
Michigan	4
Georgia	4

Clinical Trial Progress for tenecteplase

Clinical Trial Phase

Clinical Trial Phase for tenecteplase
Clinical Trial Phase	Trials
PHASE4	3
PHASE3	19
PHASE2	5

Clinical Trial Status

Clinical Trial Status for tenecteplase
Clinical Trial Phase	Trials
Recruiting	31
Completed	24
NOT_YET_RECRUITING	21

Clinical Trial Sponsors for tenecteplase

Sponsor Name

Sponsor Name for tenecteplase
Sponsor	Trials
Boehringer Ingelheim	16
Beijing Tiantan Hospital	16
Genentech, Inc.	15

Sponsor Type

Sponsor Type for tenecteplase
Sponsor	Trials
Other	170
Industry	46
UNKNOWN	7

Tenecteplase Market Analysis and Financial Projection

Last updated: February 7, 2026

What Is the Current Status of Tenecteplase in Clinical Trials?

Tenecteplase (TNK-tPA) is a genetically engineered Variant of tissue plasminogen activator (tPA). It is used to dissolve blood clots in acute myocardial infarction (AMI), ischemic stroke, and pulmonary embolism.

Clinical Development and Approvals

• FDA Approval: In 2000, the U.S. Food and Drug Administration (FDA) approved tenecteplase for acute myocardial infarction (AMI) based on its fibrin specificity and ease of administration. It is marketed under the brand name TNKase by Genentech.
• Ongoing Trials: Several late-stage trials investigate tenecteplase for stroke, pulmonary embolism, and off-label uses.
  • NOR-TEST-2 (NCT03740848): Large-scale Phase 3 trial for ischemic stroke comparing tenecteplase versus alteplase.
  • TASTE (NCT03915152): Evaluates tenecteplase efficacy in pulmonary embolism.
  • Upcoming Trials: Trials are underway to expand indications and optimize dosing strategies.

Clinical Data and Outcomes

• Tenecteplase demonstrates similar or superior efficacy compared to alteplase in several trials for MI, with improved ease of administration, and lower bleeding complications in some settings.
• Clinical trial data suggest promising results in stroke and pulmonary embolism, but regulatory approval for these remains pending.

How Does Market Consumption of Tenecteplase Look?

Market Penetration and Key Regions

• United States: Market dominance by Genentech's TNKase, with annual sales surpassing $300 million in recent years.
• Europe: Approved and marketed under different names; increasing adoption in urgent care settings.
• Asia-Pacific: Growing markets driven by increasing adoption in hospitals and emerging economies.

Competitive Landscape

• Major Competitors: Alteplase (Activase), reteplase (Retavase), and streptokinase.
• Market Share: Tenecteplase holds approximately 30-40% of the thrombolytic market for MI in North America and parts of Europe, competing primarily with alteplase.

Pricing and Reimbursement

• Pricing varies by region; in the U.S., a single 50 mg vial costs approximately $1,200-$1,400.
• Reimbursement policies increasingly favor drugs that offer simplified dosing and reduced adverse events.

What Are the Market Drivers and Barriers?

Drivers

• Ease of Use: Single-bolus administration advantages over intravenous infusion.
• Clinical Benefits: Lower risk of hemorrhagic complications reported in some trials.
• Regulatory Approvals: Expanding indications could broaden usage; off-label preferences in some settings.

Barriers

• Competition: Alteplase remains the standard for stroke despite the superior convenience of tenecteplase.
• Regulatory Hurdles: Approval delays for stroke and pulmonary indications.
• Reimbursement Challenges: Cost-effectiveness analyses influence prescribing patterns.

What Are Future Market Projections?

Market Size and Growth

• The global thrombolytic market was valued at approximately $2.5 billion in 2022.
• Compound annual growth rate (CAGR) projected at around 6.5% through 2030.

Tenecteplase Market Trends

• Increased adoption in acute MI is expected to continue, driven by clinical data.
• Emerging use in stroke and pulmonary embolism could add an estimated 15-20% annual market growth within these subsegments over the next five years.
• Potential approval of additional indications may significantly expand its market share.

Regional Forecasts

Region	2023 Market Size (USD million)	2030 Projection (USD million)	CAGR 2023-2030
North America	350	600	8.9%
Europe	250	450	8.0%
Asia-Pacific	150	370	13.7%

Source: MarketResearch.com, GlobalData (2023)

Summary and Key Takeaways

• Tenecteplase has FDA approval for myocardial infarction and ongoing trials for stroke and pulmonary embolism.
• It captures significant share in the thrombolytic market due to convenience and promising clinical outcomes.
• Competition from alteplase remains high, with ongoing efforts to expand indications and demonstrate superior efficacy/safety.
• Market growth is driven by expanding clinical applications and regional adoption, especially in emerging economies.
• Future revenue depends on regulatory approvals, clinical trial success, and payer policies.

FAQs

1. When might tenecteplase receive approval for stroke treatment?
   Pending late-stage trial results, regulatory filings could occur by 2024-2025, but approval depends on trial outcomes.

2. How does tenecteplase compare to alteplase in clinical efficacy?
   Trials suggest similar or improved efficacy with a lower bleeding risk in some settings, plus easier single-bolus dosing.

3. What are the main challenges facing tenecteplase?
   Competition from established drugs like alteplase, regulatory delays for new indications, and reimbursement uncertainties.

4. Will emerging indications significantly increase market size?
   Yes; expanding into stroke and pulmonary embolism markets could increase total addressable market by 15-20% annually.

5. What is the typical cost for treatment with tenecteplase?
   About $1,200 to $1,400 per single 50 mg vial in the U.S., with regional variations affecting overall cost and reimbursement.

References

[1] FDA Product Label for TNKase, 2000.
[2] MarketResearch.com, Global Thrombolytic Market Report, 2023.
[3] ClinicalTrials.gov Database, 2023.
[4] Pharma Intelligence, 2023 Market Analysis.